Yale Jen
Stock Analyst at Laidlaw
(0.25)
# 4,325
Out of 4,534 analysts
75
Total ratings
28.2%
Success rate
-8.6%
Average return
Main Sectors:
Stocks Rated by Yale Jen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NCEL NewcelX | Initiated Coverage: Buy | $23 | $3.97 | +479.35% | 2 | Jul 13, 2026 | |
| KZIA Kazia Therapeutics | Initiated Coverage: Buy | $25 | $13.55 | +84.50% | 1 | Apr 15, 2026 | |
| FEMY Femasys | Initiated Coverage: Buy | $130 | $3.27 | +3,875.54% | 1 | Nov 20, 2025 | |
| NSRX Nasus Pharma | Initiated Coverage: Buy | $22 | $3.01 | +630.90% | 1 | Sep 29, 2025 | |
| VKTX Viking Therapeutics | Reiterated: Buy | $110 | $36.38 | +202.36% | 3 | Aug 20, 2025 | |
| SNTI Senti Biosciences Holdings | Initiated Coverage: Buy | $5 | $0.4338 | n/a | 1 | Jun 6, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterated: Buy | $11 | $1.70 | n/a | 4 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiated Coverage: Buy | $19 | $18.03 | n/a | 1 | Mar 17, 2025 | |
| LFWD Lifeward | Initiated Coverage: Buy | $10 | $7.55 | n/a | 1 | Feb 10, 2025 | |
| XAIR Beyond Air | Maintained: Buy | $16 → $100 | $5.98 | n/a | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $68 | $52.95 | n/a | 8 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 → $20 | $4.52 | n/a | 5 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $131.50 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.03 | n/a | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $5.97 | n/a | 6 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $12.66 | n/a | 3 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.5 → $225 | $1.26 | n/a | 3 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $25 | $0.00001 | n/a | 5 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $25 | $0.20 | n/a | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.56 | n/a | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.00806 | n/a | 2 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $4.70 | n/a | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.03 | n/a | 3 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 → $10 | $0.0151 | n/a | 2 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 → $20 | $0.4864 | n/a | 3 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.68 | $8.75 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6107 | n/a | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $8.5 | $1.20 | n/a | 2 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0042 | n/a | 2 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $0.8331 | n/a | 1 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 → $90 | $3.83 | n/a | 2 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.49 | n/a | 1 | Sep 27, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $3.5 | $3.05 | n/a | 1 | Sep 16, 2014 |
NewcelX
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $23
Current: $3.97
Upside: +479.35%
Kazia Therapeutics
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $25
Current: $13.55
Upside: +84.50%
Femasys
Nov 20, 2025
Initiated Coverage: Buy
Price Target: $130
Current: $3.27
Upside: +3,875.54%
Nasus Pharma
Sep 29, 2025
Initiated Coverage: Buy
Price Target: $22
Current: $3.01
Upside: +630.90%
Viking Therapeutics
Aug 20, 2025
Reiterated: Buy
Price Target: $110
Current: $36.38
Upside: +202.36%
Senti Biosciences Holdings
Jun 6, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $0.4338
Upside: n/a
Aldeyra Therapeutics
Apr 4, 2025
Reiterated: Buy
Price Target: $11
Current: $1.70
Upside: n/a
Nuvectis Pharma
Mar 17, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $18.03
Upside: n/a
Lifeward
Feb 10, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $7.55
Upside: n/a
Beyond Air
Nov 12, 2024
Maintained: Buy
Price Target: $16 → $100
Current: $5.98
Upside: n/a
Oct 8, 2024
Reiterated: Buy
Price Target: $68
Current: $52.95
Upside: n/a
Sep 27, 2024
Reiterated: Buy
Price Target: $22 → $20
Current: $4.52
Upside: n/a
Jul 29, 2024
Initiated Coverage: Buy
Price Target: $48
Current: $131.50
Upside: n/a
Jul 23, 2024
Downgraded: Hold
Price Target: n/a
Current: $1.03
Upside: n/a
Jul 2, 2024
Reiterated: Buy
Price Target: $79
Current: $5.97
Upside: n/a
Jun 26, 2024
Reiterated: Buy
Price Target: $50
Current: $12.66
Upside: n/a
Jun 14, 2024
Reiterated: Buy
Price Target: $7.5 → $225
Current: $1.26
Upside: n/a
Jun 12, 2024
Maintained: Buy
Price Target: $11 → $25
Current: $0.00001
Upside: n/a
May 28, 2024
Initiated Coverage: Buy
Price Target: $25
Current: $0.20
Upside: n/a
Dec 22, 2023
Downgraded: Hold
Price Target: n/a
Current: $4.56
Upside: n/a
Dec 12, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.00806
Upside: n/a
Aug 28, 2023
Initiated Coverage: Buy
Price Target: $10
Current: $4.70
Upside: n/a
Aug 15, 2023
Downgraded: Hold
Price Target: n/a
Current: $2.03
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: $30 → $10
Current: $0.0151
Upside: n/a
Mar 14, 2022
Reiterated: Buy
Price Target: $18 → $20
Current: $0.4864
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: $5.68
Current: $8.75
Upside: n/a
Aug 24, 2020
Downgraded: Hold
Price Target: n/a
Current: $0.6107
Upside: n/a
Jul 31, 2020
Maintained: Buy
Price Target: $6 → $8.5
Current: $1.20
Upside: n/a
Aug 9, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0042
Upside: n/a
May 20, 2019
Initiated Coverage: Buy
Price Target: $10
Current: $0.8331
Upside: n/a
Nov 15, 2018
Maintained: Buy
Price Target: $4 → $90
Current: $3.83
Upside: n/a
Sep 27, 2016
Maintained: Hold
Price Target: n/a
Current: $5.49
Upside: n/a
Sep 16, 2014
Initiated Coverage: Buy
Price Target: $3.5
Current: $3.05
Upside: n/a